Walkersville, MD, United States of America

Matthew Hewitt

USPTO Granted Patents = 4 

Average Co-Inventor Count = 4.6

ph-index = 1


Company Filing History:


Years Active: 2023-2025

Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Matthew Hewitt

Introduction

Matthew Hewitt is a notable inventor based in Walkersville, MD (US), recognized for his significant contributions to the field of cell engineering. With a total of four patents to his name, Hewitt has made strides in developing technologies that enhance cell culture processes and viral vector production.

Latest Patents

Hewitt's latest patents include a cell culture chamber with improved cell-contacting surfaces. This innovation provides cell culture chambers designed for automated cell engineering systems, featuring surfaces that promote cell growth, adherence, differentiation, and maintenance of phenotype. The improved surfaces may include a surface coating that enhances these properties, as well as a non-porous, gas-permeable material. Additionally, he has developed an automated method for producing viral vectors, utilizing engineered viral vector-producing cell lines within a fully-enclosed cell engineering system. This method allows for the production of various viral vectors, including lentivirus, adeno-associated virus, baculovirus, and retrovirus vectors.

Career Highlights

Hewitt has worked with prominent companies in the biotechnology sector, including Lonza Walkersville, Inc. and Octane Biotech Inc. His experience in these organizations has contributed to his expertise in cell culture and viral vector technologies.

Collaborations

Throughout his career, Hewitt has collaborated with talented individuals such as Eytan Abraham and Young Shin. These partnerships have likely fostered innovation and the exchange of ideas in their respective fields.

Conclusion

Matthew Hewitt's work exemplifies the impact of innovative thinking in biotechnology. His patents and career achievements highlight his commitment to advancing cell engineering and viral vector production technologies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…